Involvement of stromal p53 in tumor-stroma interactions

Seminars in Cell and Developmental Biology

Volumn 21, Issue 1, 2010, Pages 47-54

  Bar, Jair ^a   Moskovits, Neta ^b   Oren, Moshe ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cancer; Cancer associated fibroblasts; p53; SDF 1; Stroma

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CANCER RADIOTHERAPY; CANCER REGRESSION; CELL INTERACTION; CELL PROLIFERATION; CELL SELECTION; COLON CANCER; COMPREHENSION; DISEASE COURSE; DRUG INHIBITION; DRUG MECHANISM; ENDOCRINE SYSTEM; FIBROSARCOMA; GENE ACTIVATION; GENE FUNCTION; GENE MUTATION; HUMAN; LEUKEMIA CELL; METASTASIS; NEOPLASM; NONHUMAN; P53 GENE; PROSTATE CANCER; PROTECTION; PROTEIN FUNCTION; REVIEW; STROMA CELL; TUMOR CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 75849129107     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2009.11.006     Document Type: Review

References (54)

1. Soussi T., and Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12 (2007) 303-312
2. Michael D., and Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13 (2003) 49-58
3. Vousden K.H., and Prives C. Blinded by the light: the growing complexity of p53. Cell 137 (2009) 413-431
4. Levine A.J., and Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9 (2009) 749-758
5. Menendez D., Inga A., and Resnick M.A. The expanding universe of p53 targets. Nat Rev Cancer 9 (2009) 724-737
6. Khwaja F.W., Svoboda P., Reed M., Pohl J., Pyrzynska B., and Van Meir E.G. Proteomic identification of the wt-p53-regulated tumor cell secretome. Oncogene 25 (2006) 7650-7661
7. Kiaris H., Chatzistamou I., Trimis G., Frangou-Plemmenou M., Pafiti-Kondi A., and Kalofoutis A. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res 65 (2005) 1627-1630
8. Kalluri R., and Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 6 (2006) 392-401
9. Komarova E.A., Diatchenko L., Rokhlin O.W., Hill J.E., Wang Z.J., Krivokrysenko V.I., et al. Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene 17 (1998) 1089-1096
10. Dameron K.M., Volpert O.V., Tainsky M.A., and Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265 (1994) 1582-1584
11. Nishizaki M., Fujiwara T., Tanida T., Hizuta A., Nishimori H., Tokino T., et al. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res 5 (1999) 1015-1023
12. Holmgren L., Jackson G., and Arbiser J. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene 17 (1998) 819-824
13. Narendran A., Ganjavi H., Morson N., Connor A., Barlow J.W., Keystone E., et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol 31 (2003) 693-701
14. Kang S.Y., Halvorsen O.J., Gravdal K., Bhattacharya N., Lee J.M., Liu N.W., et al. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci USA 106 (2009) 12115-12120
15. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
16. Waldman T., and Kinzler K.W. Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55 (1995) 5187-5190
17. Trimis G., Chatzistamou I., Politi K., Kiaris H., and Papavassiliou A.G. Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors. Hum Mol Genet 17 (2008) 3596-3600
18. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B.R., et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377 (1995) 646-649
19. Tan M., Wang Y., Guan K., and Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci USA 97 (2000) 109-114
20. Zou Z., Gao C., Nagaich A.K., Connell T., Saito S., Moul J.W., et al. p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 275 (2000) 6051-6054
21. Nishimori H., Shiratsuchi T., Urano T., Kimura Y., Kiyono K., Tatsumi K., et al. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15 (1997) 2145-2150
22. Pal S., Datta K., and Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 61 (2001) 6952-6957
23. Ueba T., Nosaka T., Takahashi J.A., Shibata F., Florkiewicz R.Z., Vogelstein B., et al. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci USA 91 (1994) 9009-9013
24. Menendez D., Krysiak O., Inga A., Krysiak B., Resnick M.A., and Schonfelder G. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci USA 103 (2006) 1406-1411
25. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14 (2000) 34-44
26. Moskovits N., Kalinkovich A., Bar J., Lapidot T., and Oren M. p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res 66 (2006) 10671-10676
27. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121 (2005) 335-348
28. Coppe J.P., Patil C.K., Rodier F., Sun Y., Munoz D.P., Goldstein J., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6 (2008) 2853-2868
29. Santhanam U., Ray A., and Sehgal P.B. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 88 (1991) 7605-7609
30. Sun Y., Cheung J.M., Martel-Pelletier J., Pelletier J.P., Wenger L., Altman R.D., et al. Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem 275 (2000) 11327-11332
31. Sun Y., Wenger L., Rutter J.L., Brinckerhoff C.E., and Cheung H.S. p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. J Biol Chem 274 (1999) 11535-11540
32. Sun Y., Zeng X.R., Wenger L., Firestein G.S., and Cheung H.S. P53 down-regulates matrix metalloproteinase-1 by targeting the communications between AP-1 and the basal transcription complex. J Cell Biochem 92 (2004) 258-269
33. Bian J., and Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 17 (1997) 6330-6338
34. Hill R., Song Y., Cardiff R.D., and Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123 (2005) 1001-1011
35. Bar J., Feniger-Barish R., Lukashchuk N., Shaham H., Moskovits N., Goldfinger N., et al. Cancer cells suppress p53 in adjacent fibroblasts. Oncogene (2008)
36. Ehnfors J., Kost-Alimova M., Persson N.L., Bergsmedh A., Castro J., Levchenko-Tegnebratt T., et al. Horizontal transfer of tumor DNA to endothelial cells in vivo. Cell Death Differ 16 (2009) 749-757
37. Camphausen K., Moses M.A., Menard C., Sproull M., Beecken W.D., Folkman J., et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res 63 (2003) 1990-1993
38. Lafkas D., Trimis G., Papavassiliou A.G., and Kiaris H. P53 mutations in stromal fibroblasts sensitize tumors against chemotherapy. Int J Cancer 123 (2008) 967-971
39. Burdelya L.G., Komarova E.A., Hill J.E., Browder T., Tararova N.D., Mavrakis L., et al. Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res 66 (2006) 9356-9361
40. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
41. Lassus P., Ferlin M., Piette J., and Hibner U. Anti-apoptotic activity of low levels of wild-type p53. EMBO J 15 (1996) 4566-4573
42. McKay B.C., Chen F., Perumalswami C.R., Zhang F., and Ljungman M. The tumor suppressor p53 can both stimulate and inhibit ultraviolet light-induced apoptosis. Mol Biol Cell 11 (2000) 2543-2551
43. Zhang Y., Griffith E.C., Sage J., Jacks T., and Liu J.O. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA 97 (2000) 6427-6432
44. Dudley A.C., Shih S.C., Cliffe A.R., Hida K., and Klagsbrun M. Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br J Cancer 99 (2008) 118-125
45. Wernert N., Locherbach C., Wellmann A., Behrens P., and Hugel A. Presence of genetic alterations in microdissected stroma of human colon and breast cancers. Anticancer Res 21 (2001) 2259-2264
46. Kurose K., Gilley K., Matsumoto S., Watson P.H., Zhou X.P., and Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 32 (2002) 355-357
47. Fukino K., Shen L., Patocs A., Mutter G.L., and Eng C. Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA 297 (2007) 2103-2111
48. Patocs A., Zhang L., Xu Y., Weber F., Caldes T., Mutter G.L., et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 357 (2007) 2543-2551
49. Hasebe T., Okada N., Tamura N., Houjoh T., Akashi-Tanaka S., Tsuda H., et al. p53 expression in tumor stromal fibroblasts is associated with the outcome of patients with invasive ductal carcinoma of the breast. Cancer Sci 100 (2009) 2101-2108
50. Hawsawi N.M., Ghebeh H., Hendrayani S.F., Tulbah A., Al-Eid M., Al-Tweigeri T., et al. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res 68 (2008) 2717-2725
51. Campbell I., Polyak K., and Haviv I. Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Res 69 (2009) 6765-6768 [Discussion 6769]
52. Campbell I.G., Qiu W., Polyak K., and Haviv I. Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358 (2008) 1634-1635 [Author reply 1636]
53. Qiu W., Hu M., Sridhar A., Opeskin K., Fox S., Shipitsin M., et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 40 (2008) 650-655
54. Eng C., Leone G., Orloff M.S., and Ostrowski M.C. Genomic alterations in tumor stroma. Cancer Res 69 (2009) 6759-6764